NCT06706284 - Glycemic and Weight Loss Effects of GLP-1R Agonist Therapy in Subjects With Spinal Cord Injury and Type 2 Diabetes | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 11, 2025

Primary Completion Date

May 1, 2028

Study Completion Date

January 1, 2029

Conditions

Spinal Cord InjuriesType 2 Diabetes

Interventions

DRUG

Semaglutide Injectable Product

A GLP-1 inhibitor used to control T2DM

OTHER

Placebo

Saline solution will be administered with the same frequency as semaglutide and participants will be instructed how to use the saline in the same manner as the active drug group.

Trial Locations (2)

78207

RECRUITING

University Health - Texas Diabetic Institute, San Antonio

78229

RECRUITING

University of Texas Health Science Center at San Antonio, San Antonio

All Listed Sponsors

collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

Marzieh Salehi

OTHER